Results 111 to 120 of about 10,751 (182)

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. [PDF]

J Comp Eff Res
An N, Chen J, Li J, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Xu R, Wang F.   +13 more
europepmc   +1 more source

Cost-effectiveness analysis of trastuzumab deruxtecan versus ramucirumab plus paclitaxel as second-line treatment for HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma. [PDF]

Front Pharmacol
Lang Y, Yang J, Liu M, Lin Y.
europepmc   +1 more source

Ramucirumab induces apoptosis in Caco-2 cells via mitochondrial impairment and caspase activation. [PDF]

Saudi Pharm J
Al-Dogmi AM, Al-Anazi KM, Qamar W, Farah MA.   +3 more
europepmc   +1 more source

Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study. [PDF]

Ther Adv Med Oncol
Siegerink SN, Kuijper SC, van den Ende T, Verhoeven RHA, Elias SG, Mohammad NH, Slingerland M, Derks S, van Laarhoven HWM.   +8 more
europepmc   +1 more source

Paradoxical Pyogenic Granuloma Associated With Ramucirumab but Not Bevacizumab: A Case Suggesting Differential Effects of VEGF Receptor and Ligand Inhibition. [PDF]

Respirol Case Rep
Nigi A, Iwamoto K, Itani H, Kondou S.
europepmc   +1 more source

Comparative efficacy and safety of first-line immunotherapy- and targeted therapy-based regimens for advanced gastric and gastroesophageal junction cancer: a network meta-analysis. [PDF]

BMC Cancer
Wang W, Zhang X, Sun X, Wang L.
europepmc   +1 more source

Anti-angiogenic therapy in thymic carcinoma: a narrative review of current evidence and emerging combinations. [PDF]

Mediastinum
Kim HS, Padda SK.
europepmc   +1 more source

Osimertinib <i>vs.</i> erlotinib combined with an angiogenesis inhibitor in <i>EGFR</i>-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study. [PDF]

Transl Lung Cancer Res
Hata T, Yamada T, Mikami K, Yokoyama T, Oba T, Goto Y, Furuya N, Futamura S, Taniguchi H, Okimoto T, Hirai S, Uda S, Okada A, Watanabe R, Ishizaki N, Kawachi H, Kijima T, Takayama K.   +17 more
europepmc   +1 more source

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903). [PDF]

Gastric Cancer
Kawamoto Y, Sawada K, Harada K, Motoo I, Ando T, Sogabe S, Kobayashi Y, Dazai M, Nakamura M, Hatanaka K, Ishiguro A, Sato A, Nakano S, Shindo Y, Hosokawa A, Ito K, Yoshikawa A, Ueda A, Iuchi K, Yokota I, Yuki S, Komatsu Y.   +21 more
europepmc   +1 more source

Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma. [PDF]

Pharmaceuticals (Basel)
Oakley O, Mahmood U, Ahmad Y, Smyth E.
europepmc   +1 more source